Showing results (801-810 of 1,122) with videos related to

Sort By:
Pageof 113
Investigational New Drugs|November 15, 2006
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumorsS Kalmadi, M Davis, A Dowlati, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Chempluschem|January 16, 2020
Bis(1,2,4-oxadiazolyl) Furoxan: A Promising Melt-Castable Eutectic Material of Low SensitivityEric C Johnson, Eric J Bukowski, Jesse J Sabatini, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|October 18, 2021
Genome-wide analysis of deletions in maize population reveals abundant genetic diversity and functional impactXiao Zhang, Yonghui Zhu, Karl A G Kremling, et al.
Anticancer Research|December 12, 2003
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosisSusan A Vaziri, Dale R Grabowski, Masahiro Tabata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinomaR A Figlin, J A Thompson, R M Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
The T cell death knell: immune-mediated tumor death in renal cell carcinomaR G Uzzo, V Kolenko, C J Froelich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancerL R Laufman, R M Bukowski, M A Collier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patientsJames H Finke, Brian Rini, Joanna Ireland, et al.
Cancer|September 1, 2010
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumabJorge A Garcia, Thomas E Hutson, Paul Elson, et al.
Pageof 113